Corporate Sponsorsview all sponsors
MSHO continuously contacts legislators, provides comments to policy makers and collaborates with payers on issues of concern to those delivering care to cancer patients.
It is important that our members are aware of meetings, web casts, and other educational opportunities specifically designed to address the complexities of cancer care.
FDA Renames and Restructures Oncology Office
The US Food and Drug Administration’s (FDA) office responsible for approving cancer therapies has been renamed the Office of Oncologic Diseases (OOD) and restructured to add new divisions, the agency announced Wednesday. READ MORE.